GlycoTherapeutics is a preclinical development company. We aim to develop novel therapeutics targeting glycobiology processes in cancer. The company was founded in 2022 as a spin-off from the Radboud University, Nijmegen. Its operations are based in Nijmegen, the Netherlands.
Despite the successes in immuno-oncology, less than 50% of individuals with cancer obtain a durable response. To fill this improvement potential, GlycoTherapeutics develops first-in-class anticancer drugs targeting sialic acid and fucose sugars. These sugars are overexpressed among many cancer types and are known to promote tumor progression by evasion of an immune response, increasing metastasis, increasing proliferation, and inducing resistance to therapies.
Dr. Johan Pijnenborg is CEO of GlycoTherapeutics. He is co-inventor of the technologies and is experienced in chemistry, biology and business development. The technology development was supported by scientific advisors Dr. Thomas Boltje & Dr. Christian Büll, both running their own independent chemical glycobiology research groups at the Radboud University. Biotech industry expert Dr. Leendert van den Bos is on board supporting business development. Emiel Rossing and Nienke Eerden are co-inventors specialized in glycobiology and carbohydrate chemistry.